| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MERCK | Medical use for tachykinin antagonists |
Sep, 2012
(11 years ago) | |
| US5538982 | MERCK | Medical use for tachykinin antagonists |
Jul, 2013
(10 years ago) | |
| US5719147 | MERCK | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr, 2015
(9 years ago) | |
| US6096742 | MERCK | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(5 years ago) | |
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(3 years from now) | |
Emend is owned by Merck.
Emend contains Aprepitant.
Emend has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Emend are:
- US7214692
- US5538982
- US5719147
- US6096742
Emend was authorised for market use on 30 June, 2006.
Emend is available in capsule;oral dosage forms.
Emend can be used as treatment or prevention of emesis, prevention of postoperative nausea and vomiting.
The generics of Emend are possible to be released after 26 September, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 28, 2018 |
| M(M-82) | Mar 19, 2013 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 30 June, 2006
Treatment: Treatment or prevention of emesis; Prevention of postoperative nausea and vomiting
Dosage: CAPSULE;ORAL
EMEND family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Sep, 2012
(11 years ago) | |
| US5538982 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Jul, 2013
(10 years ago) | |
| US5512570 | MERCK AND CO INC | Treatment of emesis with morpholine tachykinin receptor antagonists |
Mar, 2014
(10 years ago) | |
| US5716942 | MERCK AND CO INC | Treatment of migraine with morpholine tachykinin receptor antagonists |
Feb, 2015
(9 years ago) | |
| US5691336 | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Mar, 2019
(5 years ago) | |
|
US5691336 (Pediatric) | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Sep, 2019
(4 years ago) | |
Emend is owned by Merck And Co Inc.
Emend contains Fosaprepitant Dimeglumine.
Emend has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Emend are:
- US7214692
- US5538982
- US5512570
- US5716942
- US5691336
- US5691336*PED
Emend was authorised for market use on 25 January, 2008.
Emend is available in powder;intravenous dosage forms.
Emend can be used as prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent.
Drug patent challenges can be filed against Emend from 03 October, 2020.
The generics of Emend are possible to be released after 02 May, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-186) | May 02, 2025 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| New Patient Population(NPP) | Apr 03, 2021 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
NCE-1 date: 03 October, 2020
Market Authorisation Date: 25 January, 2008
Treatment: Prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent
Dosage: POWDER;INTRAVENOUS
EMEND family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6096742 | MSD MERCK CO | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(3 years from now) | |
Emend is owned by Msd Merck Co.
Emend contains Aprepitant.
Emend has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Emend are:
- US6096742
Emend was authorised for market use on 17 December, 2015.
Emend is available in for suspension;oral dosage forms.
Emend can be used as prevention of nausea and vomiting associated with chemotherapy (cinv).
The generics of Emend are possible to be released after 26 September, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 28, 2018 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION;ORAL
EMEND family patents